Psychiatric and Substance Use Disorders in Individuals with Hepatitis C
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 66 (2) , 155-174
- https://doi.org/10.2165/00003495-200666020-00003
Abstract
No abstract availableKeywords
This publication has 136 references indexed in Scilit:
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Is the management of hepatitis C patients appropriate? A population‐based studyAlimentary Pharmacology & Therapeutics, 2005
- Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis CJournal of Hepatology, 2005
- IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicityMolecular Psychiatry, 2004
- Association of interferon-α-induced depression and improved treatment response in patients with hepatitis CNeuroscience Letters, 2004
- The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis CJournal of Hepatology, 2004
- Adherence to combination therapy: influence on sustained virologic response and economic impactGastroenterology Clinics of North America, 2004
- Peginterferon ??-2a (40kD) [Pegasys??] Improves HR-QOL Outcomes Compared with Unmodified Interferon ??-2a [Roferon??-A]PharmacoEconomics, 2003
- Response to interferon α therapy is influenced by the iron content of the liverJournal of Hepatology, 1994
- A Rating Scale for Mania: Reliability, Validity and SensitivityThe British Journal of Psychiatry, 1978